The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions
The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions
复制标题
DOI：
10.1016/j.taap.2023.116585
复制
发表时间：
2023-06-16
影响因子：
3.8
通讯作者：
Wang，Qian Qian
中科院分区：
文献类型：
--
作者：
Wu，Ri Han;Zhu，Chen Ying;Wang，Qian Qian
急性髓性白血病（AML）是一种高度异质性的血液系统恶性肿瘤亚型，具有广泛的细胞遗传学和分子异常，这使得其难以管理和治愈。随着对AML发病机制的分子机制的深入了解，大量新的靶向治疗方法已经出现，这大大扩展了AML的医学选择并改变了AML的治疗前景。尽管如此，由基因组突变或旁路信号激活引起的耐药和难治性病例仍然是一个巨大的挑战。因此，迫切需要发现新的治疗靶点，优化联合策略，开发有效的治疗方法。这篇综述详细和全面地讨论了靶向治疗作为单一药物或与其他药物联合使用的优点和局限性。此外，还介绍了包括热疗、基于单克隆抗体的治疗和CAR-T细胞治疗在内的创新治疗方法，这可能为AML患者的治疗提供安全可行的选择。
Acute myeloid leukemia (AML) is a highly heterogeneous subtype of hematological malignancies with a wide spectrum of cytogenetic and molecular abnormalities, which makes it difficult to manage and cure. Along with the deeper understanding of the molecular mechanisms underlying AML pathogenesis, a large cohort of novel targeted therapeutic approaches has emerged, which considerably expands the medical options and changes the therapeutic landscape of AML. Despite that, resistant and refractory cases caused by genomic mutations or bypass signalling activation remain a great challenge. Therefore, discovery of novel treatment targets, optimization of combination strategies, and development of efficient therapeutics are urgently required. This review provides a detailed and comprehensive discussion on the advantages and limitations of targeted therapies as a single agent or in combination with others. Furthermore, the innovative therapeutic approaches including hyperthermia, monoclonal antibody-based therapy, and CAR-T cell therapy are also introduced, which may provide safe and viable options for the treatment of patients with AML.